TY - JOUR
T1 - Recombinant interleukin-2 continuous infusion in ovarian cancer patients with minimal residual disease at second-look
AU - Benedetti Panici, P.
AU - Scambia, G.
AU - Greggi, S.
AU - Di Roberto, P.
AU - Ragusa, G.
AU - Perrone, L.
AU - Sonsini, C.
AU - Rumi, C.
AU - Pourreau, C.
AU - Palmer, P.
AU - Franks, C. R.
AU - Mancuso, S.
PY - 1989
Y1 - 1989
N2 - Recent reports suggest that recombinant interleukin-2 may be effective in the treatment of cancer patients with low tumor burden. Considering the poor long-term survival, 11 ovarian cancer patients with minimal residual disease at second-look have so far been selected for rIL-2 intravenous continuous infusion therapy: two induction courses (3 × 106U/m2/day: 120 h+ 108 h) followed by three maintenance courses (3 × 106U/m2/day: 120 h) and third-look laparotomy. At present, three patients are still on treatment, three have completed it, and five have discontinued treatment. Sixty-seven per cent of the planned dose was administered in 49 cycles of which 42 (86%) required dose modifications due to hypotension (≥grade III) and nephrotoxicity ( > grade I). CNS and GI toxicity, allergies and fever, even though requiring dose modifications in a few cases, significantly affected patient compliance. The rebound lymphocytosis was clearly dose-related and a significant percentage increase after rIL-2 was detected only for IL-2 receptor positive cells. To date, four patients are evaluable for response after a median follow-up of 7 months, two progressed during the maintenance period, while one CR and one progression were detected in the two patients so far submitted to third-look laparotomy.
AB - Recent reports suggest that recombinant interleukin-2 may be effective in the treatment of cancer patients with low tumor burden. Considering the poor long-term survival, 11 ovarian cancer patients with minimal residual disease at second-look have so far been selected for rIL-2 intravenous continuous infusion therapy: two induction courses (3 × 106U/m2/day: 120 h+ 108 h) followed by three maintenance courses (3 × 106U/m2/day: 120 h) and third-look laparotomy. At present, three patients are still on treatment, three have completed it, and five have discontinued treatment. Sixty-seven per cent of the planned dose was administered in 49 cycles of which 42 (86%) required dose modifications due to hypotension (≥grade III) and nephrotoxicity ( > grade I). CNS and GI toxicity, allergies and fever, even though requiring dose modifications in a few cases, significantly affected patient compliance. The rebound lymphocytosis was clearly dose-related and a significant percentage increase after rIL-2 was detected only for IL-2 receptor positive cells. To date, four patients are evaluable for response after a median follow-up of 7 months, two progressed during the maintenance period, while one CR and one progression were detected in the two patients so far submitted to third-look laparotomy.
UR - http://www.scopus.com/inward/record.url?scp=0024470291&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024470291&partnerID=8YFLogxK
U2 - 10.1016/0305-7372(89)90032-7
DO - 10.1016/0305-7372(89)90032-7
M3 - Article
C2 - 2788502
AN - SCOPUS:0024470291
VL - 16
SP - 123
EP - 127
JO - Cancer Treatment Reviews
JF - Cancer Treatment Reviews
SN - 0305-7372
IS - SUPPL. A
ER -